TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

METHAZOLAMIDE

METHAZOLAMIDE
Ophthalmology Approved 1993-06-30
7
Indications
--
Phase 3 Trials
32
Years on Market

Details

Status
Prescription
First Approved
1993-06-30
Routes
ORAL
Dosage Forms
TABLET

METHAZOLAMIDE Approval History

Loading approval history...

What METHAZOLAMIDE Treats

1 indications

METHAZOLAMIDE is approved for 1 conditions since its original approval in 1993. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Glaucoma
Source: FDA Label
πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

METHAZOLAMIDE FDA Label Details

Pro

Indications & Usage

Methazolamide Tablets are indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.